Infinity Pharmaceuticals, Inc.

Equities

INFI.Q

US45665G3039

Biotechnology & Medical Research

End-of-day quote OTC Markets Other stock markets 18:00:00 2024-07-11 EDT			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	-99.96%

03-25	North American Morning Briefing : Tech in Focus on -2-	DJ
03-25	Infinity Pharmaceuticals, Inc. Went Out of Business	CI

Infinity Pharmaceuticals : To Present At 35th Annual J.P. Morgan Annual Healthcare Conference

January 05, 2017 at 08:31 am

CAMBRIDGE, Mass., Jan. 5, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at the 35(th) Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2017, at 10:30 a.m. PT (1:30 p.m. ET) in San Francisco, CA. A live webcast of Infinity's presentation will be accessible on the Investors/Media section of Infinity's website at www.infi.com, and will be available for 30 days following the event.

About Infinity
Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing IPI-549, an oral immuno-oncology development candidate that selectively inhibits PI3K-gamma. A Phase 1 study in patients with advanced solid tumors is ongoing. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Contact:
Jaren Irene Madden, Senior Director,
Investor Relations and Corporate Communications
617-453-1336 or Jaren.Madden@infi.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/infinity-to-present-at-35th-annual-jp-morgan-annual-healthcare-conference-300385521.html

SOURCE Infinity Pharmaceuticals, Inc.

Latest news about Infinity Pharmaceuticals, Inc.

North American Morning Briefing : Tech in Focus on -2-	03-25	DJ
Infinity Pharmaceuticals, Inc. Went Out of Business	03-25	CI
Revised Liquidation Plan Approved for Infinity Pharmaceuticals, Inc.	03-06	CI
Motion for Di Minimis Assets Sale Approved for Infinity Pharmaceuticals, Inc.	02-21	CI
An unknown healthcare investment firm acquired Substantially all of the assets of Infinity Pharmaceuticals, Inc. (OTCPK:INFI.Q).	02-14	CI
First Motion for Exclusivity Period Extension Approved For Infinity Pharmaceuticals, Inc.	02-12	CI
Disclosure Statement Approved on Interim Basis for Infinity Pharmaceuticals, Inc.	02-01	CI
First Motion for Exclusivity Period Extension Filed by Infinity Pharmaceuticals, Inc.	01-25	CI
North American Morning Briefing : Tech Likely to -2-	01-19	DJ
North American Morning Briefing : Stock Futures Waver Ahead of Bank-Earnings Bonanza	01-12	DJ
Joint Liquidation Plan and Disclsoure Statement Filed by Infinity Pharmaceuticals, Inc.	01-10	CI
Motion for Asset Sale Approved for Infinity Pharmaceuticals, Inc.	01-07	CI
North American Morning Briefing : Bond Yields Rise -2-	01-05	DJ
North American Morning Briefing : Stock Futures Gain as 2023 Draws to a Close	12-29	DJ
North American Morning Briefing : Stock Futures -2-	12-18	DJ
North American Morning Briefing : Investors Await -2-	12-11	DJ
North American Morning Briefing : Stock Futures, -2-	12-04	DJ
North American Morning Briefing : Stock Futures -2-	11-27	DJ
North American Morning Briefing : Stocks Futures Steady on Rates Optimism	11-20	DJ
North American Morning Briefing : Stock Futures -2-	11-13	DJ
Bidding Procedure Approved for Infinity Pharmaceuticals, Inc.	23-10-23	CI
Motion for Joint Administration Approved for Infinity Pharmaceuticals, Inc.	23-10-02	CI
Infinity Pharmaceuticals, Inc. Announces Resignation of Adelene Perkins from the Board	23-09-29	CI
INFINITY PHARMACEUTICALS LISTS BOTH ESTIMATED ASSETS AND LIABILI…	23-09-29	RE
Motion for Asset Sale Filed by Infinity Pharmaceuticals, Inc.	23-09-29	CI

Chart Infinity Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing medicines for people with cancer. The Company is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase I/Ib clinical study.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
INFINITY PHARMACEUTICALS, INC.	-99.96%	90
MODERNA, INC.	+26.63%	46.56B
LONZA GROUP AG	+45.26%	41.67B
IQVIA HOLDINGS INC.	-0.47%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+34.37%	32.4B
ICON PUBLIC LIMITED COMPANY	+20.78%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+49.53%	14.52B
MEDPACE HOLDINGS, INC.	+47.01%	13.74B
BIO-TECHNE CORPORATION	+1.76%	12.17B

Other Biotechnology & Medical Research

Infinity Pharmaceuticals, Inc.

Equities

INFI.Q

US45665G3039

Biotechnology & Medical Research

Infinity Pharmaceuticals : To Present At 35th Annual J.P. Morgan Annual Healthcare Conference

Latest news about Infinity Pharmaceuticals, Inc.

Chart Infinity Pharmaceuticals, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research